Edgewise (EWTX) CEO Receives RSUs and Option; Sell-to-Cover Executed
Rhea-AI Filing Summary
Edgewise Therapeutics insider transactions: Kevin Koch, President and CEO and director, reported multiple equity awards and a sell-to-cover on 08/12/2025. He received 17,968 RSUs that vested (or were deemed acquired) and an additional 87,500 RSUs granted with staggered vesting beginning 08/12/2026. He was also granted a 525,000-share stock option exercisable at $13.39 per share with monthly vesting starting 09/12/2025. To satisfy tax withholding, 7,972 shares were sold at an average price of $13.3924. Following these transactions, he beneficially owned 30,615 shares directly and 259,554 shares indirectly through family entities.
Positive
- Large equity awards granted to align the CEO's incentives with shareholder value (17,968 vested RSUs, 87,500 RSUs granted, 525,000-share option)
- Sell-to-cover was tax-motivated and not a discretionary sale, per the filer’s explanation
- Substantial indirect ownership (259,554 shares) via family entities indicates continued alignment with company performance
Negative
- Potential dilution from conversion of RSUs (total RSUs reported) and exercise of a large option (525,000 shares at $13.39)
- Shares sold (7,972) reduce the reporting person’s direct share count, although sold to cover taxes
Insights
TL;DR Insider received significant equity compensation and performed a routine sell-to-cover to satisfy tax obligations; transactions are largely compensatory.
The reported transactions show a mix of immediate and long-dated compensation: vested/vestable RSUs and a sizable option package (525,000 shares at $13.39). The sell-to-cover of 7,972 shares was used solely for statutory tax withholding, per the filing, and the average sale price was $13.3924. The grants create potential future dilution as RSUs convert to common shares and options are exercised. Ownership disclosure indicates substantial indirect holdings (259,554 shares), which maintains alignment with shareholders but also increases potential share supply if options are exercised.
TL;DR Transactions appear routine for an executive: compensation grants with multi-year vesting and a tax-driven sell-to-cover; no red flags disclosed.
The filing documents standard executive compensation mechanics: time-based RSUs with four-year staggered vesting schedules (starting 08/12/2025 and 08/12/2026) and an option with 1/48 monthly vesting from 09/12/2025. The reporting person corrected a prior duplicate reporting item for 26,410 indirectly held shares. There is no indication in this Form 4 of discretionary sales beyond the sell-to-cover, and the signature is by an attorney-in-fact, consistent with procedural practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 17,968 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 87,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 525,000 | $0.00 | -- |
| Exercise | Common Stock | 17,968 | $0.00 | -- |
| Sale | Common Stock | 7,972 | $13.3924 | $107K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
